{"doi":"10.1093/ajh/hpab147","title":"Effects of Vitamin D Supplementation on Orthostatic Hypotension: Results From the STURDY Trial","abstract":"BACKGROUND: Vitamin D3 supplementation is considered a potential intervention to prevent orthostatic hypotension (OH) based on observational evidence that vitamin D levels are inversely associated with OH. With data from The Study to Understand Fall Reduction and Vitamin D in You (STURDY), a double-blind, randomized, response-adaptive trial, we determined if higher doses of vitamin D3 reduced risk of OH. METHODS: STURDY tested the effects of higher (1,000+ IU/day, i.e., 1,000, 2,000, and 4,000 IU/day combined) vs. lower-dose vitamin D3 (200 IU/day, comparison) on fall risk in adults ages 70 years and older with low serum 25-hydroxyvitamin D (25(OH)D, 10-29 ng/ml). OH was determined at baseline, 3, 12, and 24 months by taking the difference between seated and standing blood pressure (BP). OH was defined as a drop in systolic or diastolic BP of at least 20 or 10 mm Hg after 1 minute of standing. Participants were also asked about OH symptoms during the assessment and the preceding month. RESULTS: Among 688 participants (mean age 77 [SD, 5] years; 44% women; 18% Black), the mean baseline systolic/diastolic BP was 130 (19)/67 (11) mm Hg, serum 25(OH)D was 22.1 (5.1) ng/ml, and 2.8% had OH. There were 2,136 OH assessments over the maximum 2-year follow-up period. Compared with 200 IU/day, 1,000+ IU/day was not associated with seated, standing, or orthostatic BP, and it did not lower risk of OH or orthostatic symptoms. CONCLUSIONS: These findings do not support use of higher doses of vitamin D3 supplementation as an intervention to prevent OH. CLINICAL TRIALS REGISTRATION: Trial Number NCT02166333.","journal":"American Journal of Hypertension","year":2021,"id":201637,"datarank":0.39587267924086733,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"self_citation_contribution":0.31191623125197543,"citation_network_contribution":0.08395644798889187,"self_endowment_contribution":0.31191623125197543,"citer_contribution":0.08395644798889187,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":3,"citers_with_citation_signal":2,"citers_with_endowment":2,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.8464,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT02166333"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":291347,"name":"Edgar R. Miller","orcid":"0000-0003-0157-6258","position":1,"is_corresponding":false},{"id":409899,"name":"Amal A. Wanigatunga","orcid":"0000-0002-5763-5184","position":2,"is_corresponding":false},{"id":264188,"name":"Jennifer A. Schrack","orcid":"0000-0001-9244-9267","position":3,"is_corresponding":false},{"id":236349,"name":"Erin D. Michos","orcid":"0000-0002-5547-5084","position":4,"is_corresponding":false},{"id":737401,"name":"Christine Mitchell","orcid":"0000-0002-8211-281X","position":5,"is_corresponding":false},{"id":336893,"name":"Rita R. Kalyani","orcid":"0000-0002-1530-6884","position":6,"is_corresponding":false},{"id":277163,"name":"Lawrence J. Appel","orcid":"0000-0002-0673-6823","position":7,"is_corresponding":false},{"id":291339,"name":"Stephen P. Juraschek","orcid":"0000-0003-4168-2696","position":0,"is_corresponding":true}],"reference_count":30,"raw_metadata":null,"created_at":"2026-07-18T23:50:56.394488Z","pmid":"34537827","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}